{"id":"remoxipride","rwe":[{"pmid":"41200990","year":"2025","title":"Dopaminergic and Opioid Systems Interact to Produce Peripheral Antinociception in Mice.","finding":"","journal":"Journal of integrative neuroscience","studyType":"Clinical Study"},{"pmid":"39662656","year":"2025","title":"Interaction between the dopaminergic and endocannabinoid systems promotes peripheral antinociception.","finding":"","journal":"European journal of pharmacology","studyType":"Clinical Study"},{"pmid":"39181172","year":"2024","title":"Exploring K(p,uu,BBB) values smaller than unity in remoxipride: A physiologically-based CNS model approach highlighting brain metabolism in drugs with passive blood-brain barrier transport.","finding":"","journal":"European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences","studyType":"Clinical Study"},{"pmid":"38819244","year":"2024","title":"Determining Ideal Management for Patients With Coexisting Prolactinomas and Psychiatric Symptoms: A Systematic Review.","finding":"","journal":"Journal of psychiatric practice","studyType":"Clinical Study"},{"pmid":"35300994","year":"2022","title":"Analgesia and pain: Dual effect of dopamine on the peripheral nociceptive system is dependent on D(2)-or D(1)-like receptor activation.","finding":"","journal":"European journal of pharmacology","studyType":"Clinical Study"}],"tags":[{"label":"remoxipride","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Sigma non-opioid intracellular receptor 1","category":"target"},{"label":"SIGMAR1","category":"gene"},{"label":"DRD3","category":"gene"},{"label":"DRD2","category":"gene"},{"label":"N05AL04","category":"atc"},{"label":"Active","category":"status"},{"label":"Antipsychotic Agents","category":"pharmacology"},{"label":"Central Nervous System Agents","category":"pharmacology"},{"label":"Central Nervous System Depressants","category":"pharmacology"},{"label":"Dopamine Agents","category":"pharmacology"},{"label":"Dopamine Antagonists","category":"pharmacology"},{"label":"Neurotransmitter Agents","category":"pharmacology"},{"label":"Psychotropic Drugs","category":"pharmacology"},{"label":"Tranquilizing Agents","category":"pharmacology"}],"phase":"marketed","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=REMOXIPRIDE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T05:20:01.111459+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T05:20:17.035952+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T05:20:07.318381+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=REMOXIPRIDE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T05:20:07.714665+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Dopamine D2 receptor antagonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T05:20:09.114885+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3989556/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T05:20:08.767723+00:00"}},"allNames":"(s)-remoxipride","offLabel":[],"synonyms":["remoxipride","(S)-Remoxipride","remoxipride hydrochloride","remoxipride HCl"],"timeline":[{"date":"1990-01-01","type":"positive","source":"DrugCentral","milestone":"YEAR INTRODUCED approval"}],"aiSummary":"Remoxipride, a marketed drug by an unspecified company, binds to the Sigma non-opioid intracellular receptor 1, positioning it uniquely in the market. Its key strength lies in its distinct mechanism of action, differentiating it from competitors like amisulpride, which is patent-protected until March 10, 2031. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generics.","approvals":[{"date":"1990-01-01","orphan":false,"company":"","regulator":"YEAR INTRODUCED"}],"brandName":"(S)-Remoxipride","ecosystem":[],"mechanism":{"target":"D(4) dopamine receptor, 5-hydroxytryptamine receptor 1A, 5-hydroxytryptamine receptor 2A","targets":[{"gene":"SIGMAR1","source":"DrugCentral","target":"Sigma non-opioid intracellular receptor 1","protein":"Sigma non-opioid intracellular receptor 1"},{"gene":"DRD3","source":"DrugCentral","target":"D(3) dopamine receptor","protein":"D(3) dopamine receptor"},{"gene":"DRD2","source":"DrugCentral","target":"D(2) dopamine receptor","protein":"D(2) dopamine receptor"},{"gene":"HTR2A","source":"DrugCentral","target":"5-hydroxytryptamine receptor 2A","protein":"5-hydroxytryptamine receptor 2A"},{"gene":"DRD4","source":"DrugCentral","target":"D(4) dopamine receptor","protein":"D(4) dopamine receptor"},{"gene":"HTR1A","source":"DrugCentral","target":"5-hydroxytryptamine receptor 1A","protein":"5-hydroxytryptamine receptor 1A"}],"modality":"Small Molecule","drugClass":"remoxipride","explanation":"","oneSentence":"","technicalDetail":"Remoxipride acts as a selective antagonist of the Sigma-1 receptor, a subtype of the sigma receptor family, which is involved in modulating neurotransmitter release and synaptic plasticity."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/2365","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=REMOXIPRIDE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T15:31:23.712546","_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T05:20:17.036022+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"amisulpride","drugSlug":"amisulpride","fdaApproval":"2020-02-26","patentExpiry":"Mar 10, 2031","patentStatus":"Patent protected","relationship":"same-class"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"remoxipride","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"amisulpride","brandName":"amisulpride","genericName":"amisulpride","approvalYear":"2020","relationship":"same-class"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"NUI":"N0000166887","NDDF":"004031","UNII":"0223RD59PE","CHEBI":"CHEBI:92948","INN_ID":"5197","RXNORM":"235832","UMLSCUI":"C0073047","chemblId":"CHEMBL3989556","ChEMBL_ID":"CHEMBL22242","KEGG_DRUG":"D02682","DRUGBANK_ID":"DB00409","PUBCHEM_CID":"54477","SNOMEDCT_US":"349884002","SECONDARY_CAS_RN":"117591-79-4","MESH_DESCRIPTOR_UI":"D017330"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","halfLife":"5.5 hours","clearance":"1.7 mL/min/kg","bioavailability":"90%","fractionUnbound":"0.16%","volumeOfDistribution":"0.65 L/kg"},"publicationCount":0,"therapeuticAreas":["Neuroscience"],"atcClassification":{"source":"DrugCentral","atcCode":"N05AL04","allCodes":["N05AL04"]},"biosimilarFilings":[],"recentPublications":[{"date":"2025 Oct 28","pmid":"41200990","title":"Dopaminergic and Opioid Systems Interact to Produce Peripheral Antinociception in Mice.","journal":"Journal of integrative neuroscience"},{"date":"2025 Jan 15","pmid":"39662656","title":"Interaction between the dopaminergic and endocannabinoid systems promotes peripheral antinociception.","journal":"European journal of pharmacology"},{"date":"2024 Dec 1","pmid":"39181172","title":"Exploring K(p,uu,BBB) values smaller than unity in remoxipride: A physiologically-based CNS model approach highlighting brain metabolism in drugs with passive blood-brain barrier transport.","journal":"European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences"},{"date":"2024 May 1","pmid":"38819244","title":"Determining Ideal Management for Patients With Coexisting Prolactinomas and Psychiatric Symptoms: A Systematic Review.","journal":"Journal of psychiatric practice"},{"date":"2022 May 5","pmid":"35300994","title":"Analgesia and pain: Dual effect of dopamine on the peripheral nociceptive system is dependent on D(2)-or D(1)-like receptor activation.","journal":"European journal of pharmacology"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"withdrawn","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"1990","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"OTHER","regulator":"YEAR INTRODUCED","status":"approved","approval_date":"1990-01-01T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T05:20:17.036022+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":false,"score":0}}